{"entity":{"id":"chiauranib","kind":"drug","name":"Chiauranib","aka":[],"tldr":"Chiauranib is an experimental small-molecule drug from Chipscreen Biosciences in phase 3 trials for ovarian cancer, aimed at VEGF / VEGFR and KIT.","summary":"Chiauranib (CS2164) is a small-molecule drug developed by Chipscreen Biosciences. Its targets are VEGF / VEGFR, KIT, PDGFRA, CSF1R and Folate receptor alpha (the sponsor names VEGFR1, VEGFR2, VEGFR3, PDGFRa, c-Kit, Aurora B, CSF-1R). The sponsor states: A novel orally active multi-target inhibitor that simultaneously inhibits angiogenesis-related kinases (VEGFR1/2/3, PDGFRa, c-Kit), the mitosis-related kinase Aurora B, and the chronic-inflammation-related kinase CSF-1R at single-digit nanomolar potency. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04921527 (Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer), in ovarian cancer. The largest, NCT04921527, plans to enrol 454 participants with primary completion was scheduled for 2024-12-31 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Chiauranib","url":"https://clinicaltrials.gov/search?intr=CS2164"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":["vegf","kit","pdgfra","csf1r","folr1"],"drugs":[],"companies":["chipscreen"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04921527"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"CS2164","modality":"small molecule","mechanism":"A novel orally active multi-target inhibitor that simultaneously inhibits angiogenesis-related kinases (VEGFR1/2/3, PDGFRa, c-Kit), the mitosis-related kinase Aurora B, and the chronic-inflammation-related kinase CSF-1R at single-digit nanomolar potency.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/chiauranib/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"target":[{"id":"csf1r","kind":"target","name":"CSF1R","route":"/targets/csf1r/"},{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/"},{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/"},{"id":"pdgfra","kind":"target","name":"PDGFRA","route":"/targets/pdgfra/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"company":[{"id":"chipscreen","kind":"company","name":"Chipscreen Biosciences","route":"/companies/chipscreen/"}],"trial":[{"id":"nct04921527","kind":"trial","name":"Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer","route":"/trials/nct04921527/"}]}}